Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 3.8/5
Grifols

Grifols (GRFS US)

30
Analysis
Health CareSpain
Grifols S.A. develops, manufactures, and markets plasma derivatives, IV Therapy, enteral nutrition, diagnostic systems, and medical materials.
more
17 Dec 2024 13:10

Liquid Universe of European Ordinary and Preferred Shares: December‘24 Report

Since mid-November, share-price spreads have generally widened across European liquid universe of ordinary and preferred shares with few changes in...

Share
bullishGrifols SA
20 Nov 2024 08:18

Lowball Non-Binding Indication from Brookfield

Rejected Offer: Grifols' independent committee rejected Brookfield's proposed valuation of €10.50 per Class A share, citing significant...

Share
bullishGrifols SA
18 Nov 2024 14:21

Liquid Universe of European Ordinary and Preferred Shares: November‘24 Report

Since mid-October, share-price spreads have generally tightened across European liquid universe of ordinary and preferred shares (10 have...

Share
bearishGrifols SA
28 Oct 2024 22:45

Brookfield Delays Its Takeover Bid for Grifols for a Second Time

Brookfield’s acquisition bid for Grifols has been delayed for a second time due to funding issues, raising investor concerns.

Share
16 Oct 2024 12:13

Liquid Universe of European Ordinary and Preferred Shares: October‘24 Report

Since mid-September, share-price spreads have generally widened across our European liquid universe of ordinary and preferred shares (9 have...

Share
x